ADORA2A and cancer: In line with this, in a study combining a dendritic cell-based therapeutic cancer vaccine with A2aR inhibition or a CD73 inhibitor, it was reported that A2aR inhibition did not enhance proliferation, whereas CD73 inhibition did.40